|
Disease |
|
|
|
Detail |
| hsa-miR-205 |
|
Unspecified |
Micro-RNA profiling in kidney and bladder cancers. |
2007 |
|
|
|
|
|
|
| hsa-miR-185 |
|
Unspecified |
Micro-RNA profiling in kidney and bladder cancers. |
2007 |
|
|
|
|
|
|
| hsa-miR-203 |
|
Unspecified |
Micro-RNA profiling in kidney and bladder cancers. |
2007 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
Micro-RNA profiling in kidney and bladder cancers. |
2007 |
|
|
|
|
|
|
| hsa-miR-23a |
|
Unspecified |
Micro-RNA profiling in kidney and bladder cancers. |
2007 |
|
|
|
|
|
|
| hsa-miR-23b |
|
Unspecified |
Micro-RNA profiling in kidney and bladder cancers. |
2007 |
|
|
|
|
|
|
| hsa-miR-26b |
|
Unspecified |
Micro-RNA profiling in kidney and bladder cancers. |
2007 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
Micro-RNA profiling in kidney and bladder cancers. |
2007 |
|
|
|
|
|
|
| hsa-miR-221 |
|
Unspecified |
Micro-RNA profiling in kidney and bladder cancers. |
2007 |
|
|
|
|
|
|
| hsa-miR-103-1 |
|
Unspecified |
Micro-RNA profiling in kidney and bladder cancers. |
2007 |
|
|
|
|
|
|
| hsa-miR-127 |
|
Causal |
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. |
2006 |
|
|
|
|
|
|
| hsa-miR-21 |
|
Causal |
Distinct microRNA alterations characterize high- and low-grade bladder cancer |
2009 |
|
|
|
|
|
|
| hsa-miR-100 |
|
Unspecified |
Distinct microRNA alterations characterize high- and low-grade bladder cancer |
2009 |
|
|
|
|
|
|
| hsa-miR-99a |
|
Unspecified |
Distinct microRNA alterations characterize high- and low-grade bladder cancer |
2009 |
|
|
|
|
|
|
| hsa-miR-205 |
|
Unspecified |
A microRNA expression ratio defining the invasive phenotype in bladder tumors. |
2008 |
|
|
|
|
|
|
| hsa-miR-21 |
|
Unspecified |
A microRNA expression ratio defining the invasive phenotype in bladder tumors. |
2008 |
|
|
|
|
|
|
| hsa-miR-143 |
|
Causal |
MicroRNA-143 as a tumor suppressor for bladder cancer. |
2009 |
|
|
|
|
|
|
| hsa-miR-10a |
|
Unspecified |
MiRNA expression in urothelial carcinomas: Important roles of miR-10a, miR-222,miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. |
2009 |
|
|
|
|
|
|
| hsa-miR-125b |
|
Unspecified |
MiRNA expression in urothelial carcinomas: Important roles of miR-10a, miR-222,miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. |
2009 |
|
|
|
|
|
|
| hsa-miR-222 |
|
Unspecified |
MiRNA expression in urothelial carcinomas: Important roles of miR-10a, miR-222,miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. |
2009 |
|
|
|
|
|
|
| hsa-miR-31 |
|
Unspecified |
MiRNA expression in urothelial carcinomas: Important roles of miR-10a, miR-222,miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. |
2009 |
|
|
|
|
|
|
| hsa-miR-452 |
|
Unspecified |
MiRNA expression in urothelial carcinomas: Important roles of miR-10a, miR-222,miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. |
2009 |
|
|
|
|
|
|
| hsa-miR-452* |
|
Unspecified |
MiRNA expression in urothelial carcinomas: Important roles of miR-10a, miR-222,miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. |
2009 |
|
|
|
|
|
|
| hsa-miR-7 |
|
Unspecified |
MiRNA expression in urothelial carcinomas: Important roles of miR-10a, miR-222,miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. |
2009 |
|
|
|
|
|
|
| hsa-miR-101 |
|
Causal |
The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. |
2009 |
|
|
|
|
|
|
| hsa-miR-125b |
|
Unspecified |
Identification of novel microRNA targets based on microRNA signatures in bladder cancer. |
2009 |
|
|
|
|
|
|
| hsa-miR-133a |
|
Causal |
Identification of novel microRNA targets based on microRNA signatures in bladder cancer. |
2009 |
|
|
|
|
|
|
| hsa-miR-133b |
|
Unspecified |
Identification of novel microRNA targets based on microRNA signatures in bladder cancer. |
2009 |
|
|
|
|
|
|
| hsa-miR-145 |
|
Unspecified |
Identification of novel microRNA targets based on microRNA signatures in bladder cancer. |
2009 |
|
|
|
|
|
|
| hsa-miR-195 |
|
Unspecified |
Identification of novel microRNA targets based on microRNA signatures in bladder cancer. |
2009 |
|
|
|
|
|
|
| hsa-miR-199a* |
|
Causal |
Identification of novel microRNA targets based on microRNA signatures in bladder cancer. |
2009 |
|
|
|
|
|
|
| hsa-miR-30-3p |
|
Causal |
Identification of novel microRNA targets based on microRNA signatures in bladder cancer. |
2009 |
|
|
|
|
|
|
| hsa-miR-26a |
|
Unspecified |
Up-regulation of microRNA in bladder tumor tissue is not common. |
2009 |
|
|
|
|
|
|
| hsa-miR-29c |
|
Unspecified |
Up-regulation of microRNA in bladder tumor tissue is not common. |
2009 |
|
|
|
|
|
|
| hsa-miR-30c |
|
Unspecified |
Up-regulation of microRNA in bladder tumor tissue is not common. |
2009 |
|
|
|
|
|
|
| hsa-miR-30e-5p |
|
Unspecified |
Up-regulation of microRNA in bladder tumor tissue is not common. |
2009 |
|
|
|
|
|
|
| hsa-miR-129 |
|
Causal |
Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. |
2009 |
|
|
|
|
|
|
| hsa-miR-145 |
|
Unspecified |
Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. |
2009 |
|
|
|
|
|
|
| hsa-miR-21 |
|
Unspecified |
Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. |
2009 |
|
|
|
|
|
|
| hsa-miR-221 |
|
Causal |
MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL |
2009 |
|
|
|
|
|
|